Detection, Monitoring, and Discrimination of Amyloidogenic vs Innocent Light Chains in Systemic Amyloidoses.

High-sensitivity detection and quantitative monitoring of amyloidogenic immunoglobulin light chains are critical for early diagnosis and relapse detection in AL amyloidosis, enabling better organ preservation.

• Why it matters: AL amyloidosis is treatable but rapidly progressive, and early identification of pathogenic monoclonal light chains is essential for survival and organ protection. Standardized relapse definitions and reliable discrimination between amyloidogenic and “innocent” light chains remain unmet needs.
• What they did: The review synthesizes mass spectrometry-based measurable residual disease detection, flow cytometry, and next-generation sequencing for deep hematologic response assessment, plus emerging LC-intrinsic features and early organ-damage biomarkers. It also discusses strategies to differentiate AL from non-AL amyloidoses, especially transthyretin (ATTR) cardiac amyloidosis.
• The result: These laboratory approaches support improved diagnosis, treatment-response monitoring, and relapse identification in systemic amyloidoses, and may enable pre-symptomatic intervention in apparently benign monoclonal gammopathies. They also promise rapid exclusion of AL amyloidosis when coexisting LC-producing clones are at elevated risk.

AI summary of the abstract · may contain errors · not medical advice · read the paper.